BLCO vs. ZBH, SNN, SOLV, PEN, STVN, IRTC, GKOS, TMDX, SLNO, and NVST
Should you be buying Bausch + Lomb stock or one of its competitors? The main competitors of Bausch + Lomb include Zimmer Biomet (ZBH), Smith & Nephew SNATS (SNN), Solventum (SOLV), Penumbra (PEN), Stevanato Group (STVN), iRhythm Technologies (IRTC), Glaukos (GKOS), TransMedics Group (TMDX), Soleno Therapeutics (SLNO), and Envista (NVST). These companies are all part of the "medical equipment" industry.
Bausch + Lomb vs. Its Competitors
Bausch + Lomb (NYSE:BLCO) and Zimmer Biomet (NYSE:ZBH) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, media sentiment, risk, institutional ownership, profitability, valuation and earnings.
Zimmer Biomet has higher revenue and earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Zimmer Biomet, indicating that it is currently the more affordable of the two stocks.
Bausch + Lomb has a beta of 0.63, suggesting that its share price is 37% less volatile than the S&P 500. Comparatively, Zimmer Biomet has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500.
In the previous week, Zimmer Biomet had 11 more articles in the media than Bausch + Lomb. MarketBeat recorded 14 mentions for Zimmer Biomet and 3 mentions for Bausch + Lomb. Zimmer Biomet's average media sentiment score of 1.19 beat Bausch + Lomb's score of 0.34 indicating that Zimmer Biomet is being referred to more favorably in the news media.
11.1% of Bausch + Lomb shares are owned by institutional investors. Comparatively, 88.9% of Zimmer Biomet shares are owned by institutional investors. 0.2% of Bausch + Lomb shares are owned by company insiders. Comparatively, 0.7% of Zimmer Biomet shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Zimmer Biomet has a net margin of 10.51% compared to Bausch + Lomb's net margin of -5.58%. Zimmer Biomet's return on equity of 12.76% beat Bausch + Lomb's return on equity.
Bausch + Lomb currently has a consensus price target of $15.70, indicating a potential upside of 0.26%. Zimmer Biomet has a consensus price target of $111.94, indicating a potential upside of 9.00%. Given Zimmer Biomet's stronger consensus rating and higher possible upside, analysts clearly believe Zimmer Biomet is more favorable than Bausch + Lomb.
Summary
Zimmer Biomet beats Bausch + Lomb on 17 of the 17 factors compared between the two stocks.
Get Bausch + Lomb News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLCO and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BLCO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bausch + Lomb Competitors List
Related Companies and Tools
This page (NYSE:BLCO) was last updated on 10/21/2025 by MarketBeat.com Staff
Free BLCO Stock Alerts